NPR logo

For Lab Mice, The Medical Advances Keep Coming

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
For Lab Mice, The Medical Advances Keep Coming

For Lab Mice, The Medical Advances Keep Coming

  • Download
  • <iframe src="" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript


Space and astronomy aren't the only scientific field to experience major breakthroughs this year. As NPR's Joe Palca tells us, 2011 was a big year for medicine, too, and for the little critters who help make so much medical research possible.

JOE PALCA, BYLINE: When scientists want to test new therapies for cancer or heart disease, they frequently turn to mice for help. For most mice, this isn't the best thing that could happen to them. Being a research subject has definite disadvantages, at least for mice. But most people prefer a new therapy be tested in a rodent rather than making a human patient the guinea pig, if you'll forgive the twisted metaphor.

So every year, mice get the latest therapies, and some of the time, they're cured. For example, Richard Vile works with a strain of lab mice that are prone to getting prostate cancer. Vile is at the Mayo Clinic in Rochester, Minnesota.

RICHARD VILE: What we've done is we've vaccinated mice against tumors.

PALCA: Vile says the vaccine is made from a special virus containing cancer cell genes. The modified virus energizes the mouse's immune system so it can fight off the cancer. The vaccine doesn't prevent cancer. Instead, Vile gives the vaccine to mice that already have tumors.

VILE: And in a proportion of the mice, in our best experiments, those tumors would actually go away.

PALCA: I know that the goal here is not specifically to cure mice, but this is good news for mice.

VILE: It is good news for mice.

PALCA: A good news doesn't end with prostrate cancer. Scientists have reported progress this year in melting away all sorts of tumors, as well as promising treatments for a variety of other ailments. For example, Lois Smith of Children's Hospital in Boston has been studying an eye problem that afflicts premature infants and people with diabetes. The problem is caused by abnormal blood vessel growth in the eye that can lead to blindness. She's turned to mice to answer some fundamental questions.

DR. LOIS SMITH: How do we promote normal blood vessel regrowth? How do we prevent the abnormal new blood vessels from growing?

PALCA: This year, she reported that giving mice Omega-3 fatty acids, that stuff you find in fish oil, was a promising approach.

SMITH: It decreases by 50 percent, the abnormal new blood vessel growth.

PALCA: This approach only works before the problem develops. It won't be much help for the three blind mice we've all heard so much about. But just as some therapies are tested in mice before they're tested in humans, some are tested in mouse cells before they're tested in live mice. Jeffrey Holt is also at Children's Hospital in Boston. He's found some genes that have the wrong DNA sequence in people with an inherited form of deafness, so he's working with mice that have the same problem.

DR. JEFFREY HOLT: The idea is then to replace those genes with the correct DNA sequence and hopefully restore function.

PALCA: This year, Holt was able to correct that problem in mouse cells.

HOLT: That was done in vitro, in a dish. And now we want to do it in the live animal.

PALCA: So how far off are you from trying that, do you think?

HOLT: We're pretty close. That's something we have planned in the next year or so.

PALCA: So for that good news, mice still have to wait a while. Joe Palca, NPR News, Washington.

Copyright © 2011 NPR. All rights reserved. Visit our website terms of use and permissions pages at for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.